[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335303-105":59,"doc-detail-335303-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clarifying-new-molecular-subtyping-and-precise-treatment-of-melanoma-based-on-disulfidptosis-related-lncrna-signature","Clarifying new molecular subtyping and precise treatment of melanoma based on disulfidptosis-related lncRNA signature","","Disulfidptosis, a newly characterized programmed cell death process, is tightly linked to the immune microenvironment in cancer cells, while long non-coding RNAs (lncRNAs) are known to influence melanoma biology. Using transcriptional, clinical, and pathological data from the TCGA-SKCM database, researchers constructed a 2-Disulfidptosis-related lncRNA (DRL) prognostic model and defined novel molecular subtypes. The model showed strong performance for melanoma prognosis. High-risk tumors exhibited reduced ESTIMATE, ImmuneScore, and StromalScore, consistent with immune suppression and exhaustion. Different subgroups displayed distinct immune activation states and drug sensitivities, providing guidance for clinical treatment and identifying DRL targets for future study.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clarifying-new-molecular-subtyping-and-precise-treatment-of-melanoma-based-on-disulfidptosis-related-lncrna-signature/335303/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clarifying-new-molecular-subtyping-and-precise-treatment-of-melanoma-based-on-disulfidptosis-related-lncrna-signature/335303.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main goal regarding melanoma and disulfidptosis?","Question",{"text":112,"@type":113},"To clarify how disulfidptosis-related lncRNAs contribute to melanoma, by building a prognostic model and novel molecular subtypes based on TCGA-SKCM data.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the DRL prognostic model developed and what did it predict?",{"text":117,"@type":113},"Through bioinformatic analysis of transcriptional, clinical, and pathological data from TCGA-SKCM, the 2-DRL prognostic model produced survival and ROC results indicating strong efficacy for predicting melanoma prognosis.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the molecular subgroups differ in immune status and drug sensitivity?",{"text":121,"@type":113},"One subgroup showed an immune-activated state, while others showed immune suppression and exhaustion, and each subgroup demonstrated different sensitivity patterns to specific targeted drugs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335303,1790151496,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Lei etal. European Journal  \nEuropean Journal of Medical Research (2024) 29:468  \n[https://doi.org/10.1186/s40001-024-02035-8](https://doi.org/10.1186/s40001-024-02035-8 of Medical Research)[ of Medical Research](https://doi.org/10.1186/s40001-024-02035-8 of Medical Research)  \n RESEARCH Open Access  \nClarifying new molecular subtyping and precise treatment of melanoma based on disulfidptosis-related lncRNA signature  \nYue Lei1†, Long Wang2†, Pei Liu1†, Yilin Song3, Yihang Gong4*, Yang Jiang5* and Shukang Li6*  \nAbstract  \nDisulfidptosis, the newest form of programmed cell death, is closely associated with the immune microenvironment of cancer cells. Long non-coding RNA (lncRNA) has also been found to play a crucial role in melanoma. However, the role of disulfidptosis-related lncRNA in melanoma remains unclear. Through bioinformatic analysis ofthe transcriptional, clinical, and pathological data from theTCGA-SKCM (The Cancer Genome Atlas—Skin cutaneous melanoma) database, we established a 2-Disulfidptosis-related lncRNA (DRL) prognostic model and a novel molecular subtype for melanoma. The survival and ROC curves ofthe 2-DRL prognostic model demonstrated its strong efficacy in predicting the prognosis of melanoma. The high-risk group of melanoma exhibited a significant decrease in ESTIMATEScore, ImmuneScore, and StromalScore, indicative of pronounced immune suppression and exhaustion. Subgroup C2 of melanoma displayed an immune-activated state, while subgroups C1 and C3 showed immune suppression and exhaustion, potentially leading to poorer prognosis. Subgroup C1 demonstrated better sensitivity to Zoledronate, UMI-77, Nilotinib, and Cytarabine. Subgroup C2 exhibited greater sensitivity to Ribociclib, XAV939, Topotecan, and Ruxolitinib. Subgroup C3 showed higher sensitivity to VX-11e, Ulixertinib, Trametinib, and Afatinib. This study revealed the immune microenvironment status and targeted drug sensitivity in melanoma patients with different risk scores and molecular subtypes, offering valuable guidance for clinical treatment and identifying significant DRL targets for future in-depth research.  \nKeywords Disulfidptosis, Melanoma, Immune microenvironment, Long non-coding RNA, Molecular subtyping  \n†Yue Lei, Long Wang and Pei Liu have authors contributed equally to this work.  \n*Correspondence: Yihang Gong [gongyhsysu@163.com](gongyhsysu@163.com)[ ](gongyhsysu@163.com)Yang Jiang [13972481427@163.com](13972481427@163.com)[ ](13972481427@163.com)Shukang Li [15926161321@163.com](15926161321@163.com)  \n1 Department of Blood Transfusion, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China  \n2 Zhongshan City People’s Hospital, Zhongshan 528400, Guangdong, China  \n3 Shantou University Medical College, 22 Xinling Road, Shantou 515063, Guangdong, China  \n4 Department of Hepatic Surgery and Liver Transplantation Center & Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital, SunYat-Sen University, Guangzhou 510630, China  \n5 Department of Dermatology, Baoan Central Hospital of Shenzhen, Shenzhen 518102, China  \n6 Dermatology Center, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and you","cbCaikgBo9J4fQ2n","https://ap.wps.com/l/cbCaikgBo9J4fQ2n","pdf",8878552,15,"English","# Abstract\n# Introduction","[{\"question\":\"What is the study’s main goal regarding melanoma and disulfidptosis?\",\"answer\":\"To clarify how disulfidptosis-related lncRNAs contribute to melanoma, by building a prognostic model and novel molecular subtypes based on TCGA-SKCM data.\"},{\"question\":\"How was the DRL prognostic model developed and what did it predict?\",\"answer\":\"Through bioinformatic analysis of transcriptional, clinical, and pathological data from TCGA-SKCM, the 2-DRL prognostic model produced survival and ROC results indicating strong efficacy for predicting melanoma prognosis.\"},{\"question\":\"How do the molecular subgroups differ in immune status and drug sensitivity?\",\"answer\":\"One subgroup showed an immune-activated state, while others showed immune suppression and exhaustion, and each subgroup demonstrated different sensitivity patterns to specific targeted drugs.\"}]","Clarifying new molecular subtyping and precise treatment of melanoma based on disulfidptosis-related lncRNA signature | PDF",1790010453,38]